-
Richard Davies, Deputy Chairman of Alvotech, chosen as Chairman of the Board
-
Gertjan Bartlema, previously at Celgene and Amgen, designated as Chief Executive Officer
-
Peter Greaney, previously at ADC Therapeutics and Celgene, designated as Chief Business Officer
-
Appointments include considerable market experience to speed up advancement of lead property IMM-101 and bring it to clients in requirement of reliable treatments
Uxbridge, UK – 10 May 2023 – Immodulon, a late-stage scientific business establishing an extremely separated cancer immunotherapy that primes the client’s own natural body immune system, today reveals it has actually chosen Richard Davies as Chairman of the Board and designated Gertjan Bartlema as Chief Executive Officer and Peter Greaney as Chief Business Officer.
This brand-new group brings years of market experience from leading international pharmaceutical business consisting of Celgene, Amgen, Hospira, ADC Therapeutics and Alvotech. Their know-how will be important in directing IMM-101 through late-stage scientific advancement and increasing its capacity for clients.
Richard Davies, Chairman of the Board, said: “I am excited to join Immodulon’s Board of Directors as Chairman at this pivotal time for the company. Immodulon has generated compelling Phase 2 data with IMM-101, which has the potential to make a real impact on the treatment of pancreatic cancer where patients have limited new treatment options. Gertjan and Peter are highly experienced biotech executives and I look forward to supporting them and the Board in realising IMM-101’s true potential, providing a new therapy for patients suffering from pancreatic cancer and maximising the return for investors.”
Gertjan Bartlema, Chief Executive Officer of Immodulon, included: “Having joined the Immodulon Board last year, I am honoured to take on the role of leading the company towards its goal of improving outcomes for patients with pancreatic cancer. I am excited to work with the team to accelerate the clinical development of IMM-101 in combination with Abraxane (nab-paclitaxel) and gemcitabine. I’m inspired by this opportunity of making a meaningful impact with this potential new treatment regimen for patients suffering from pancreatic cancer.”
Richard Davies
Richard has more than thirty years’ pharmaceutical market experience and is presently Deputy Chairman of the Board of Directors for Alvotech. Richard worked as CEO of BONESUPPORT AB, a public Scandinavian orthobiologics business, CEO of Auregen SA, a tissue engineering business and Chief Commercial Officer of Hospira, at the time the world’s biggest injectable drug maker, consequently obtained by Pfizer. Additionally, Richard invested 9 years at Amgen in a series of senior management functions throughout different locations after starting his early profession at Eli Lilly.
Richard holds a BSc in Applied Chemistry from the University of Portsmouth and an MBA from the University of Warwick.
Gertjan Bartlema
Gertjan is an international biotech leader with over 25 years’ market experience in financing, business advancement and operations. Most just recently, Gertjan was CEO of VICO Therapeutics BV, an independently held Netherlands-based business. Prior to VICO, Gertjan invested 12 years at Celgene where he began as part of their preliminary European management group based in Switzerland. As a member of its New Jersey based business business advancement group, he played an essential function in the acquisition of Abraxis BioScience, including Abraxane to Celgene’s portfolio. Gertjan began his profession at Amgen and over a 9-year duration held different functions at its European (Switzerland) and home offices in the United States.
Gertjan holds an MSc in Economics from Maastricht University, Netherlands.
Peter Greaney, PhD
Peter is an extremely skilled business advancement executive, with over twenty years’ worldwide market know-how. Previously, Peter worked as Head of Corporate Development at ADC Therapeutics where he played an important function changing the business from a personal R&D biotech to a NYSE-listed public biotech with an industrial healing item. Prior to ADC Therapeutics, Peter invested 12 years at Celgene in a variety of functions of increasing duty in Switzerland and the United States throughout medical, industrial and business advancement and played an essential function incorporating Abraxane into the Celgene portfolio. Peter started his profession as a Preclinical Senior Scientist at Apoxis.
Peter holds a BSc in Cell Biology from the University of East Anglia and a PhD in Molecular and Cellular Biology from the University of Nottingham.
–Ends –
Notes to Editors
About Immodulon Therapeutics Ltd
Immodulon is a late-stage scientific business establishing an extremely separated cancer immunotherapy technique that primes the client’s own natural body immune system with the objective to considerably boost the effectiveness of a broad series of anti-cancer treatments, consisting of chemotherapy and checkpoint inhibitors.
Immodulon is establishing IMM-101, a heat-killed formula of the mycobacterium M. obuense, as a broad-spectrum immunomodulatory representative that has appealing capacity in a series of difficult-to-treat tumours consisting of those thought about to be immunologically “cold,” such as pancreatic ductal adenocarcinoma.
Immodulon has actually produced appealing, positive Phase 2 information with IMM-101 in pancreatic cancer in mix with gemcitabine. These information reveal that IMM-101 is safe and reliable, lengthening progression-free survival for a sub-group of clients with metastatic illness compared to gemcitabine alone. IMM-101 is because of go into a critical pancreatic cancer research study.
Contacts:
Immodulon
Gertjan Bartlema, CEO
[email protected]
Peter Greaney, CBO
[email protected]
MEDiSTRAVA Consulting
Frazer Hall, Sandi Greenwood, Eleanor Perkin
Immodulon@medistrava.com
+44 (0)203 928 6900
